| AMAG Pharmaceuticals is a pharmaceutical company focused on product candidates across a range of therapeutic areas. Co.'s products support the health of patients in the areas of hematology and maternal and women's health, including Feraheme® (ferumoxytol injection) for intravenous use, Makena® (hydroxyprogesterone caproate injection) auto-injector, Intrarosa® (prasterone) vaginal inserts and Vyleesi® (bremelanotide injection). In addition to its approved products, Co.'s portfolio includes two product candidates, AMAG-423 (digoxin immune fab (ovine)), which is being studied for the treatment of severe preeclampsia, and ciraparantag, which is being studied as an anticoagulant reversal agent. We show 46 historical shares outstanding datapoints in our AMAG shares outstanding history coverage, used to compute AMAG market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AMAG market cap history over the course of time is important for investors
interested in comparing AMAG's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AMAG versus a peer is one thing; comparing
AMAG market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AMAG can fluctuate over the course of history.
With this page we aim to empower investors researching AMAG by allowing them to research the AMAG market cap history.